MEDIPOST Treats First Patient with Injectable Cell Therapeutic for Knee Osteoarthritis

MEDIPOST Registers the Chinese Patent for a Mesenchymal Stem Cell Culture Method

MEDIPOST to Expand the GMP facility to increase manufacturing capacity for CARTISTEM and new pipeline of products

MEDIPOST Receives Approval for Phase III Clinical Trial of CARTISTEM for the Treatment of Osteochondral Cartilage Defects in Ankle Joint

MEDIPOST Clears Phase II Clinical Trial Approval for CARTISTEM in Japan

MEDIPOST Completes Phase 2a Clinical Trial of NEUROSTEM for Alzheimer’s Disease

MEDIPOST’s Clinical Trial of Next-Generation Cell Therapy Product ‘SMUP-IA-01’ Makes Solid Progress

MEDIPOST Completes Phase 2a Clinical Trial of NEUROSTEM for Alzheimer’s Disease

MEDIPOST Initiates Phase-2 Clinical Trial of CARTISTEM in Japan

MEDIPOST completes the phase 1 clinical trial of its injectable drug for knee osteoarthritis, SMUP-IA-01

MEDIPOST receives approval for processing the phase 3 clinical trial of CARTISTEM in Japan

MEDIPOST speeds up its global commercialization of CARTISTEM by requesting official product approval in Malaysia